Gain Therapeutics, Inc. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common stock and emerging growth company status. Recent Form 8-K disclosures cover financial results, business updates, Regulation FD materials, scientific presentations, and clinical or biomarker updates related to GT-02287 and Parkinson’s disease.
The company’s proxy materials describe annual meeting matters, director elections, board composition, executive compensation, equity awards and auditor ratification. Other filings record governance changes, including board membership updates, and identify the company’s registered common stock, Delaware incorporation and reporting framework.
Gain Therapeutics reported new exploratory data from its Phase 1b study of GT-02287 in people with Parkinson’s disease. All participants who started with elevated levels of glucosylsphingosine (GluSph) in cerebrospinal fluid showed large decreases back toward levels seen in healthy individuals after 90 days of treatment, meeting a prespecified exploratory endpoint.
The Phase 1b trial enrolled 21 participants, with 19 completing the 90-day dosing period and 15 (79%) choosing to enter a nine‑month extension expected to conclude in September 2026. GT-02287 has been generally well-tolerated over 90 days at plasma exposures within the projected therapeutic range, and the data monitoring committee recommended the study continue with no changes.
Earlier Phase 1 data in healthy volunteers showed favorable safety, central nervous system exposure in the projected therapeutic range, and increased glucocerebrosidase (GCase) activity at clinically relevant doses. Gain Therapeutics stated it has sufficient capital to fund operations through completion of the Phase 1b extension and through year-end 2026.
Gain Therapeutics reported new exploratory data from its Phase 1b study of GT-02287 in people with Parkinson’s disease. All participants who started with elevated levels of glucosylsphingosine (GluSph) in cerebrospinal fluid showed large decreases back toward levels seen in healthy individuals after 90 days of treatment, meeting a prespecified exploratory endpoint.
The Phase 1b trial enrolled 21 participants, with 19 completing the 90-day dosing period and 15 (79%) choosing to enter a nine‑month extension expected to conclude in September 2026. GT-02287 has been generally well-tolerated over 90 days at plasma exposures within the projected therapeutic range, and the data monitoring committee recommended the study continue with no changes.
Earlier Phase 1 data in healthy volunteers showed favorable safety, central nervous system exposure in the projected therapeutic range, and increased glucocerebrosidase (GCase) activity at clinically relevant doses. Gain Therapeutics stated it has sufficient capital to fund operations through completion of the Phase 1b extension and through year-end 2026.
Gain Therapeutics (GANX) reported Q3 2025 results showing continued investment in R&D and an increased net loss. Net loss was $5.28 million (vs. $4.49 million a year ago), or $(0.15) per share. Operating expenses were $4.79 million. For the first nine months, net loss totaled $15.62 million.
Cash and cash equivalents were $8.81 million at September 30, 2025. The company disclosed that this balance will not fund operations for 12 months from issuance; management stated substantial doubt about continuing as a going concern and plans to seek additional financing and reduce costs to extend runway beyond the first quarter of 2026.
To bolster liquidity year-to-date, GANX raised capital via an ATM program ($4.91 million net) and a July 2025 public offering of 4,501,640 shares and warrants (gross $7.0 million, $6.0 million net), plus an over-allotment of 675,246 shares and additional warrants (gross $1.1 million, $1.0 million net). Cash used in operating activities for the nine months was $13.85 million. Shares outstanding were 35,976,390 as of September 30, 2025; as context, 36,097,536 were outstanding as of October 31, 2025.
Gain Therapeutics, Inc. filed a current report to furnish a press release announcing its financial results for the third quarter ended September 30, 2025, along with a business update. The press release, dated November 12, 2025, is included as Exhibit 99.1. The company states that this information is being furnished under the rules governing current reports and is not considered filed for liability purposes or automatically incorporated into other securities law filings unless specifically referenced.
Gain Therapeutics, Inc. filed Amendment No. 1 to a mixed shelf registration (Form S-3) to register up to $100,000,000 of securities, including common stock, preferred stock, warrants, debt securities, subscription rights, and units, which may be offered and sold from time to time.
The company may sell securities directly, through agents, dealers, or underwriters, and may use market-based methods such as at-the-market offerings, with terms set in future prospectus supplements. Net proceeds, if and when securities are sold, are expected to be used for working capital and general corporate purposes.
GANX is listed on Nasdaq (symbol “GANX”); the last reported sale price was $1.90 per share on November 6, 2025. As of November 3, 2025, 36,241,000 shares of common stock were outstanding; this figure provides baseline context and is separate from the shelf registration capacity.
Gain Therapeutics (GANX) furnished a virtual KOL event presentation under Item 7.01 Regulation FD. On October 14, 2025, the company hosted “Biomarkers, Clinical Endpoints, and the Path to Disease Modification: Contextualizing the emerging data from GT-02287,” featuring Karl Kieburtz, M.D., M.P.H. (University of Rochester) and Kenneth Marek, M.D. (Institute for Neurodegenerative Disorders).
The slide deck from the event was furnished as Exhibit 99.1. The information provided under Item 7.01, including Exhibit 99.1, is being furnished to the SEC and is not deemed filed or subject to Section 18 liability, nor incorporated by reference unless specifically referenced.
Gain Therapeutics, Inc. reported a change in its Board of Directors. On October 6, 2025, director Eric Richman resigned from the Board effective immediately. The company states that his resignation was not due to any disagreement with Gain Therapeutics regarding its operations, policies, or practices. On October 7, 2025, in connection with his departure, the company reduced the size of the Board from eight to seven members, reflecting the vacancy without appointing a replacement.
Gain Therapeutics reported preliminary results from its ongoing Phase 1b study of GT-02287 in people with Parkinson’s disease, with or without a GBA1 mutation. After 90 days of dosing, GT-02287 has been safe and generally well tolerated, with no treatment-emergent serious adverse events. Some participants showed transient increases in alkaline phosphatase and other liver enzymes, which returned to normal even while treatment continued.
The 21 participants include treatment-naïve patients, individuals on deep brain stimulation, and most on levodopa and other Parkinson’s drugs. Several participants experienced improvements in their MDS-UPDRS Part II and III scores by Day 90, while mean Part I scores were unchanged. The company notes that the mean improvement in Parts II and III by Day 90, not seen by Day 30, suggests a potential disease-slowing effect consistent with preclinical models and the proposed mechanism of GT-02287. Plasma pharmacokinetics were consistent across sampled participants and within the projected therapeutic range.
A data monitoring committee has twice recommended continuing the study, and Australian health authorities have approved an extension allowing patients to be treated for up to 12 months.
Gain Therapeutics reported operating losses and tightened liquidity in the first half of 2025 while continuing clinical development of its lead program. For the six months ended June 30, 2025 the company recorded a $10.34 million net loss, with total operating expenses of $9.46 million. Cash and cash equivalents were $6.69 million at June 30, 2025, down from $10.39 million at year-end 2024, and total assets were $9.83 million versus total liabilities of $6.14 million, leaving stockholders' equity of $3.70 million.
The company disclosed a going concern assessment, stating its June 30, 2025 cash is insufficient to fund operations for 12 months and that it will need additional capital to continue beyond Q1 2026. Management noted recent financings including ATM sales and a July 2025 public offering that generated net proceeds (July offering net proceeds of $6.1 million plus an additional $1.0 million from over-allotment) and described actions to optimize costs and pursue collaborations. The lead clinical candidate GT-02287 completed a Phase 1 study (n=72) that was reported as safe and generally well tolerated, supporting further development.
Gain Therapeutics, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a business update; that press release is included as Exhibit 99.1 to this Current Report. The filing also references an Interactive Data File as Exhibit 104.
The registrant indicates it is an emerging growth company and its common stock trades under GANX on The NASDAQ Stock Market. The company states the press release and related information are furnished and therefore are not deemed filed for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings except by specific reference. This 8-K does not include the financial statements or numeric results within its text.